{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:12:29Z","timestamp":1779091949237,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm Regener"],"DOI":"10.1186\/s41232-026-00421-9","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:16:19Z","timestamp":1778300179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy profile of S-005151 (Redasemtide), in patients with chronic liver diseases: phase 2 trial"],"prefix":"10.1186","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9279-5917","authenticated-orcid":false,"given":"Atsunori","family":"Tsuchiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruhiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Setsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroteru","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitomi","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuto","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-635X","authenticated-orcid":false,"given":"Shuji","family":"Terai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"421_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516\u201337.","journal-title":"J Hepatol"},{"key":"421_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","volume":"5","author":"Collaborators GBDC","year":"2020","unstructured":"Collaborators GBDC. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245\u201366.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"421_CR3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Terrault NA, Tacke F, et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20:388\u201398.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"421_CR4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/s41591-019-0599-8","volume":"25","author":"F Moroni","year":"2019","unstructured":"Moroni F, Dwyer BJ, Graham C, et al. Safety profile of autologous macrophage therapy for liver cirrhosis. Nat Med. 2019;25:1560\u20135.","journal-title":"Nat Med"},{"key":"421_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S2468-1253(17)30326-6","volume":"3","author":"PN Newsome","year":"2018","unstructured":"Newsome PN, Fox R, King AL, et al. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2018;3:25\u201336.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"421_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2019.06.017","volume":"84","author":"V Ratziu","year":"2019","unstructured":"Ratziu V, Sanyal AJ, Loomba R, et al. REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 2019;84:105803.","journal-title":"Contemp Clin Trials"},{"key":"421_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.874408","volume":"13","author":"L Shan","year":"2022","unstructured":"Shan L, Wang F, Zhai D, et al. New drugs for hepatic fibrosis. Front Pharmacol. 2022;13:874408.","journal-title":"Front Pharmacol"},{"key":"421_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41536-021-00132-4","volume":"6","author":"S Takeuchi","year":"2021","unstructured":"Takeuchi S, Tsuchiya A, Iwasawa T, et al. Small extracellular vesicles derived from interferon-gamma pre-conditioned mesenchymal stromal cells effectively treat liver fibrosis. NPJ Regen Med. 2021;6:19.","journal-title":"NPJ Regen Med"},{"key":"421_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/sctm.18-0105","volume":"8","author":"Y Watanabe","year":"2019","unstructured":"Watanabe Y, Tsuchiya A, Seino S, et al. Mesenchymal stem cells and induced bone marrow-derived macrophages synergistically improve liver fibrosis in mice. Stem Cells Transl Med. 2019;8:271\u201384.","journal-title":"Stem Cells Transl Med"},{"key":"421_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s41232-021-00177-4","volume":"41","author":"S Nojiri","year":"2021","unstructured":"Nojiri S, Tsuchiya A, Natsui K, et al. Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice. Inflamm Regen. 2021;41:28.","journal-title":"Inflamm Regen"},{"key":"421_CR11","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/hepr.13825","volume":"52","author":"Y Ishii","year":"2022","unstructured":"Ishii Y, Tsuchiya A, Natsui K, et al. Synthesized HMGB1 peptide prevents the progression of inflammation, steatosis, fibrosis, and tumor occurrence in a non-alcoholic steatohepatitis mouse model. Hepatol Res. 2022;52:985\u201397.","journal-title":"Hepatol Res"},{"key":"421_CR12","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.1073\/pnas.1016753108","volume":"108","author":"K Tamai","year":"2011","unstructured":"Tamai K, Yamazaki T, Chino T, et al. PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci U S A. 2011;108:6609\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"421_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nri1594","volume":"5","author":"MT Lotze","year":"2005","unstructured":"Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331\u201342.","journal-title":"Nat Rev Immunol"},{"key":"421_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep11008","volume":"5","author":"E Aikawa","year":"2015","unstructured":"Aikawa E, Fujita R, Kikuchi Y, et al. Systemic high-mobility group box 1 administration suppresses skin inflammation by inducing an accumulation of PDGFRalpha(+) mesenchymal cells from bone marrow. Sci Rep. 2015;5:11008.","journal-title":"Sci Rep"},{"key":"421_CR15","volume":"42","author":"M Mito","year":"2025","unstructured":"Mito M, Tsuchiya A, Ishii S, et al. Multidirectional therapeutic effects of synthesized HMGB1 peptide on liver cirrhosis in mice. Biochem Biophys Rep. 2025;42:102061.","journal-title":"Biochem Biophys Rep"},{"key":"421_CR16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696\u20139.","journal-title":"J Hepatol"},{"key":"421_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/hep.1840010511","volume":"1","author":"RG Knodell","year":"1981","unstructured":"Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431\u20135.","journal-title":"Hepatology"},{"key":"421_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100328","volume":"3","author":"G Fossdal","year":"2021","unstructured":"Fossdal G, Mjelle AB, Wiencke K, et al. Fluctuating biomarkers in primary sclerosing cholangitis: a longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF. JHEP Rep. 2021;3:100328.","journal-title":"JHEP Rep"},{"key":"421_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202838","volume":"13","author":"T Kido","year":"2018","unstructured":"Kido T, Miyagawa S, Goto T, et al. The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster. PLoS ONE. 2018;13:e0202838.","journal-title":"PLoS ONE"},{"key":"421_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230392","volume":"15","author":"T Goto","year":"2020","unstructured":"Goto T, Miyagawa S, Tamai K, et al. High-mobility group box 1 fragment suppresses adverse post-infarction remodeling by recruiting PDGFRalpha-positive bone marrow cells. PLoS ONE. 2020;15:e0230392.","journal-title":"PLoS ONE"},{"key":"421_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nature00858","volume":"418","author":"P Scaffidi","year":"2002","unstructured":"Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418:191\u20135.","journal-title":"Nature"},{"key":"421_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/01.shk.0000225404.51320.82","volume":"26","author":"M Yu","year":"2006","unstructured":"Yu M, Wang H, Ding A, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006;26:174\u20139.","journal-title":"Shock"},{"key":"421_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.gastro.2008.03.076","volume":"135","author":"L Huwart","year":"2008","unstructured":"Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135:32\u201340.","journal-title":"Gastroenterology"},{"key":"421_CR24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.21037\/qims.2019.05.13","volume":"9","author":"HM Ghoz","year":"2019","unstructured":"Ghoz HM, Kroner PT, Stancampiano FF, et al. Hepatic iron overload identified by magnetic resonance imaging-based T2* is a predictor of non-diagnostic elastography. Quant Imaging Med Surg. 2019;9:921\u20137.","journal-title":"Quant Imaging Med Surg"},{"key":"421_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/jmri.23731","volume":"37","author":"SK Venkatesh","year":"2013","unstructured":"Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging. 2013;37:544\u201355.","journal-title":"J Magn Reson Imaging"},{"key":"421_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2036.2004.01882.x","volume":"19","author":"AH Malik","year":"2004","unstructured":"Malik AH, Kumar KS, Malet PF, et al. Correlation of percutaneous liver biopsy fragmentation with the degree of fibrosis. Aliment Pharmacol Ther. 2004;19:545\u20139.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Inflammation and Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41232-026-00421-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-026-00421-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-026-00421-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:05:05Z","timestamp":1779091505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41232-026-00421-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["421"],"URL":"https:\/\/doi.org\/10.1186\/s41232-026-00421-9","relation":{},"ISSN":["1880-8190"],"issn-type":[{"value":"1880-8190","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was approved by Niigata University Medical and Dental Hospital\u2019s Institutional Review Board (IRB reference number: I020-003) and registered with the Japan Registry of Clinical Trials (registry number: jRCT2031200232). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript and consent to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AT and ST received funding from Shionogi & Co., Ltd. ST received funding from StemRim Inc. ST is the Editor for the journal. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}